Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | MicrobiomeTrials← Back to trialsNCT05023551
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2021-09-08Est. Completion: 2027-09-30
Enrollment target: 39 participants Locations- University of California at San Francisco, San Francisco, California, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- Columbia University, New York, New York, United States
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan
- Kyoto University Hospital, Kyoto, Sakyo-ku, Japan
- National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Other microbiome trials you might be interested in
MelanomaGliomaThyroid CancerNon-Small Cell Lung CancerMalignant NeoplasmsBrain NeoplasmsAdvanced or Metastatic Solid TumorsHGGLGGLow Grade GliomaHigh Grade GliomaDifferentiated Thyroid CancerNSCLC (Non-small Cell Lung Cancer)
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in co…
Birmingham, United StatesEst. completion Aug 2, 2027
Glioblastoma Multiforme (GBM)Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body an…
Houston, United StatesEst. completion Dec 31, 2026